title: Antiproliferative action of Xylopia aethiopica fruit extract on human cervical cancer cells.
abstract: The anticancer potential of Xylopia aethiopica fruit extract (XAFE), and the mechanism of cell death it elicits, was investigated in various cell lines. Treatment with XAFE led to a dose-dependent growth inhibition in most cell lines, with selective cytotoxicity towards cancer cells and particularly the human cervical cancer cell line C-33A. In this study, apoptosis was confirmed by nuclear fragmentation and sub-G(0)/G(1) phase accumulation. The cell cycle was arrested at the G(2)/M phase with a decreased G(0)/G(1) population. A semi-quantitative gene expression study revealed dose-dependent up-regulation of p53 and p21 genes, and an increase in the Bax/Bcl-2 ratio. These results indicate that XAFE could be a potential therapeutic agent against cancer since it inhibits cell proliferation, and induces apoptosis and cell cycle arrest in C-33A cells.
authors.affiliation: Drug Target Discovery and Development Division, Central Drug Research Institute (CDRI-CSIR), Lucknow, India.
authors.forename: Oluwatosin A
authors.initials: OA
authors.lastname: Adaramoye
authors.forename: Jayanta
authors.initials: J
authors.lastname: Sarkar
authors.forename: Neetu
authors.initials: N
authors.lastname: Singh
authors.forename: Sanjeev
authors.initials: S
authors.lastname: Meena
authors.forename: Bendangla
authors.initials: B
authors.lastname: Changkija
authors.forename: Prem P
authors.initials: PP
authors.lastname: Yadav
authors.forename: Sanjeev
authors.initials: S
authors.lastname: Kanojiya
authors.forename: Sudhir
authors.initials: S
authors.lastname: Sinha
mesh_terms: D000972:Antineoplastic Agents, Phytogenic / Q000494:pharmacology / Q000627:therapeutic use*; D017209:Apoptosis / Q000187:drug effects*; D002453:Cell Cycle / Q000187:drug effects*; D002455:Cell Division / Q000187:drug effects; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D050759:Cyclin-Dependent Kinase Inhibitor p21 / Q000378:metabolism; D004268:DNA-Binding Proteins / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D005260:Female; D005638:Fruit; D016195:G2 Phase / Q000187:drug effects; D015870:Gene Expression / Q000187:drug effects; D006801:Humans; D009687:Nuclear Proteins / Q000378:metabolism; D008517:Phytotherapy; D010936:Plant Extracts / Q000494:pharmacology / Q000627:therapeutic use*; D000072160:Tumor Protein p73; D025521:Tumor Suppressor Proteins / Q000378:metabolism; D015854:Up-Regulation; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D054336:Xylopia
chemical_list: D000972:Antineoplastic Agents, Phytogenic; C493956:CDKN1A protein, human; D050759:Cyclin-Dependent Kinase Inhibitor p21; D004268:DNA-Binding Proteins; D009687:Nuclear Proteins; D010936:Plant Extracts; D000072160:Tumor Protein p73; D025521:Tumor Suppressor Proteins